Startups — April 5, 2021
Ohio State startup Entrada Therapeutics announces $116M in new funding
The new funding will help take the technology into the clinical setting.
A biotechnology company based on research created at The Ohio State University recently announced $116 million in new investment.
Entrada Therapeutics Inc., a privately held biotechnology company dedicated to treating diseases by delivering drugs into target cells, said the investment will support treatment of multiple neuromuscular diseases, led by Duchenne muscular dystrophy (DMD).
The company was co-founded by Dehua Pei, Charles H. Kimberly Professor in Chemistry and Biochemistry at Ohio State. When it was founded, Entrada raised $59 million from investors, the largest amount raised in the initial round of financing for an Ohio State startup.
Read the full story on Ohio State News.